Literature DB >> 18575828

Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study.

Mohamed Ali Bedaiwy1, Mahmoud Rezk Abd-Elwahed Hussein, Charles Biscotti, Tommaso Falcone.   

Abstract

Endometriotic foci, especially ovarian ones, with epithelial cytologic atypia may be precursors of cancer. This study presents an overview of the atypical cytological and histopathological findings associated with endometriosis. Six cases of endometriosis, with atypical histological and cytological changes, were obtained from the archives of the Department of Pathology at Cleveland Clinic Foundation between year 2000 and 2003. The size of the base from which these cases were drawn was 2000 cases of endometriosis. The age range of the patients was from 29 to 52 years. The clinical presentations included infertility (three cases), pelvic pain (three cases), adenexal and pelvic masses (four cases). Stage IV endometriosis with extensive pelvic involvement was found in two patients. Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul de sac (four cases); urinary bladder (two cases); sigmoid colon, hemidiaphragms, and uterine vessels (one case each). The endometriotic lesions were associated with uterine leiomyomas (two patients) and adenocarcinoma of the vagina (one patient). Histologically, in addition to endometrial type glands and stroma, usually found in endometriosis, we observed both cytologic and pattern atypism involving the epithelium in all cases. The features of cytologic atypia included nuclear stratification, hyperchromatism, and pleomorphism. The features of pattern atypia were complex glandular pattern, papillary formations and psammoma bodies. In two cases, these features were sufficient for diagnosis of borderline Mullerian seromucinous tumours. One patient had recurred with metastatic adenocarcinoma of the vault. She died later from disseminated metastatic disease. There is a rare association between pelvic endometriosis and borderline ovarian tumours (three cases), cytologic and pattern atypia (two cases); mesothelial hyperplasia, endosalpingiosis (two cases), and metastasis (one case). Cytologic and pattern atypia can develop in the endometriotic foci and therefore, these lesions should be thoroughly scrutinized for presence of these changes. Our findings recommend surgical excision of these foci rather than their simple cauterization.

Entities:  

Mesh:

Year:  2008        PMID: 18575828     DOI: 10.1007/s12253-008-9072-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  43 in total

1.  Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.

Authors:  Atsushi Higashiguchi; Taketo Yamada; Nobuyuki Susumu; Taisuke Mori; Atsushi Suzuki; Daisuke Aoki; Michiie Sakamoto
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

2.  Diagnosis of pelvic endometriosis with use of macroscopic versus histologic findings.

Authors:  Gian Luigi Marchino; Gianluca Gennarelli; Raffaella Enria; Francesca Bongioanni; Giovanni Lipari; Marco Massobrio
Journal:  Fertil Steril       Date:  2005-07       Impact factor: 7.329

3.  Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.

Authors:  W G McCluggage; C Bryson; H Lamki; D D Boyle
Journal:  Int J Gynecol Pathol       Date:  2000-07       Impact factor: 2.762

4.  Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma.

Authors:  Meike Körner; Elisabeth Burckhardt; Luca Mazzucchelli
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

Review 5.  Role of endometriosis in cancer and tumor development.

Authors:  Lillian Marie Swiersz
Journal:  Ann N Y Acad Sci       Date:  2002-03       Impact factor: 5.691

6.  Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas.

Authors:  R Ria; G Loverro; A Vacca; D Ribatti; G Cormio; A M Roccaro; L Selvaggi
Journal:  Eur J Clin Invest       Date:  2002-03       Impact factor: 4.686

7.  Endometrioid adenocarcinoma of the ovary and endometriosis.

Authors:  P Valenzuela; P Ramos; S Redondo; Y Cabrera; I Alvarez; A Ruiz
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-07-17       Impact factor: 2.435

8.  Endometrium from women with and without endometriosis, and peritoneal, ovarian and bowel endometriosis, show different c-kit protein expression.

Authors:  Catherine Uzan; Annie Cortez; Charlotte Dufournet; Raffaèle Fauvet; Jean-Pierre Siffroi; Emile Daraï
Journal:  J Reprod Immunol       Date:  2005-02       Impact factor: 4.054

9.  Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Shinsuke Aida; Hideyuki Shimazaki; Seiichi Tamai; Osamu Matsubara
Journal:  Hum Pathol       Date:  2007-04-18       Impact factor: 3.466

Review 10.  Etiology and pathogenesis of epithelial ovarian cancer.

Authors:  Samuel C Mok; Joseph Kwong; William R Welch; Goli Samimi; Laurent Ozbun; Tomas Bonome; Michael J Birrer; Ross S Berkowitz; Kwong-Kwok Wong
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

View more
  2 in total

1.  MR imaging findings of extraovarian endocervical mucinous borderline tumors arising from pelvic endometriosis.

Authors:  Dong Myung Yeo; Sung Eun Rha; Jae Young Byun; Ahwon Lee; Mee-Ran Kim
Journal:  Korean J Radiol       Date:  2013-11-05       Impact factor: 3.500

Review 2.  Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development.

Authors:  Amy Dawson; Marta Llauradó Fernandez; Michael Anglesio; Paul J Yong; Mark S Carey
Journal:  Ecancermedicalscience       Date:  2018-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.